Seattle Genetics says SGN-30 showed antitumor response in phase 2 trial

By Elaine Rigoli

Tampa, Fla., May 4 - Seattle Genetics, Inc. reported data from its ongoing phase 2 clinical trial, evaluating SGN-30 in cutaneous anaplastic large cell lymphoma (ALCL) and other lymphoproliferative disorders, which showed that multiple patients achieved objective antitumor responses to SGN-30 therapy, including both complete and partial responses.

The study includes patients with relapsed or refractory CD30-expressing cutaneous T-cell disease, including cutaneous ALCL, transformed mycosis fungoides and lymphomatoid papulosis, the company said in a news release.

"We are encouraged by our data in this relapsed and refractory patient population, especially the high response rate with SGN-30 and the significant durations of response observed in several patients," president and chief executive officer Clay B. Siegall said in the release.

"SGN-30 may provide an important therapeutic option for advanced cutaneous T-cell malignancies, which are often painful, disfiguring and can greatly impact patients' quality of life."

Seattle Genetics is a biotechnology company based in Bothell, Wash.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.